Pharos iBio to Participate in 'Bio Korea 2026'... Showcasing AI Drug Discovery Platform
CSO Jongcheol Chae to Join Panel Discussion as an Expert in AI-Driven Drug Discovery
Pharos iBio, a company specializing in artificial intelligence (AI)-powered drug discovery, announced on the 29th that it is participating in "Bio Korea 2026," which is being held at COEX in Seoul until April 30. The company will showcase its AI and quantum computing-based research technologies and key achievements during the event.
During the event, Pharos iBio has set up a dedicated booth to present its proprietary AI drug discovery platform, Chemiverse®, as well as its major pipelines. The company will also hold partnership meetings with global collaborators. On the 29th, Chief Scientific Officer (CSO) Jongcheol Chae will join a session titled "Changes in Drug Discovery Paradigms Driven by the Spread of AI and Quantum Computing Technologies" as a panelist, where he plans to discuss strategies for improving the efficiency of drug development using AI platforms and approaches to identifying new drug candidates.
CSO Chae is a quantum computing expert leading the advancement of Chemiverse at Pharos iBio. In this session, he will also share insights on the productivity and economic efficiency of R&D in AI-driven drug discovery, as well as achievements in pipeline optimization using Chemiverse.
Pharos iBio's leading pipelines include "Lasmotinib," a treatment for acute myeloid leukemia (AML); "PHI-501," a therapy for refractory solid tumors; and "PHI-601," a next-generation menin inhibitor. Lasmotinib, a therapy targeting FLT3 mutations, demonstrated safety and efficacy in its global Phase 1 clinical trial and is now preparing to enter a global Phase 2 trial. The company explained that there is confirmed synergy potential, as the anti-cancer efficacy increases when Lasmotinib is combined with a menin inhibitor.
PHI-501 is an oral solid tumor therapy currently under development, designed to simultaneously inhibit BRAF and DDR1/2, which are key signaling pathways in cancer cells. PHI-601 is an anti-cancer drug candidate from the menin inhibitor class.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kyutae Kim, Head of Business Development at Pharos iBio, stated, "Bio Korea is a venue where you can get a comprehensive view of the latest technological trends and research directions in the global bio-health industry. Through our participation this year, we aim to actively pursue open innovation opportunities, further advance drug discovery, and accelerate the expansion of global partnerships."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.